|[February 27, 2013]
Blaze Bioscience Announces Two Poster Presentations at AACR-SNMMI Conference and Award of NCI SBIR Contract Advancing Tumor PaintTM Technology
SEATTLE --(Business Wire)--
Bioscience, Inc., a biotechnology company dedicated to developing
innovative products to improve the lives of cancer patients, announced
today that two posters on aspects of the development of Tumor PaintTM
technology will be presented at the American Association of Cancer
Research and Society of Nuclear Medicine and Molecular Imaging
(AACR-SNMMI) joint conference. These poster presentations are additional
recognition of the scientific work that started in the laboratory of
Blaze Bioscience co-founder Dr. Jim Olson of the Fred Hutchinson Cancer
Research Center and is being continued at Blaze.
The conference "State-of-the-Art Molecular Imaging in Cancer Biology and
Therapy" is being held in San Diego, February 27 to March 2, 2013.
Members of Dr. Olson's lab are co-authors and presenters on the posters:
"Evaluation of candidate near-infrared dyes for clinical translation
of Tumor PaintTM technology," by Stacey Hansen, Mark
Stroud, Julia Parrish-Novak, Claudia Jochheim, and Jim Olson; and
"A Tumor PaintTM product provides near-infrared
flurescence detection of tumor tissue in mouse models of skin
cancer," by Christopher G. Hubert, Stacey Hansen, Mark Stroud, Julia
Parrish-Novak, and Jim Olson.
The potential utility of the Tumor Paint technology has been further
recognized by the National Cancer Institute (NCI), which has awarded
Blaze a $248,551 Phase 1 Small Business Innovation Research contract to
study Tumor Paint technology in canine patients with multiple tumor types1.
Dogs undergoing tumor resection as part of their treatment for cancer
are candidates for this study. The study, which is fully funded by the
NCI contract, is being conducted at Washington State University's
College of Veterinary Medicine, one of the nation's top veterinary
schools, and is open for enrollment.
"These scientific presentations and the NCI award are important
validations of the Tumor Paint technology and demonstrations of Blaze's
continued commitment to expanding our knowledge related to the Tumor
Paint platform," said Julie Novak, Blaze Bioscience Vice President of
Research and Project Management. "Researchers Mark Stroud and Stacey
Hansen have moved seamlessly from their positions in Dr. Olson's lab to
continue their scientific contributions as part of the Blaze team. In
addition, the NCI contract provides a rare opportunity to study a Tumor
Paint product candidate in a real-world veterinary surgical setting."
About Blaze Bioscience
Blaze Bioscience, Inc. is a Seattle-based, privately held biotechnology
company dedicated to developing products that assist physicians in their
quest to improve the lives of cancer patients. The company was founded
in 2010 to develop and commercialize the Tumor Paint technology, which
has potential applications in a broad array of solid tumor cancers.
Tumor Paint technology is designed to provide real-time, high-resolution
intraoperative visualization of cancer cells, enabling better detection
and more complete and precise surgical removal of cancer. The first
Tumor Paint product candidate, BLZ-100, is under development for cancer
surgery in multiple solid tumor types. For additional information,
please visit www.blazebioscience.com.
1 This project has been funded in whole with Federal funds
from National Cancer Institute, National Institutes of Health,
Department of Health and Human Services, under Contract No.
[ Back To TMCnet.com's Homepage ]